Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study evaluating HRS9531 injection in participants with mild, moderate, and normal hepatic function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• HRS9531 Injection (HRS9531)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Diabetes Mellitus, Weight Loss | Phase 1 | Status: NOT_YET_RECRUITING